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Abstract
In December 2017, the National Academy of Neuropsychology convened an interorganizational Summit on Population Health Solutions
for Assessing Cognitive Impairment in Geriatric Patients in Denver, Colorado. The Summit brought together representatives of a broad
range of stakeholders invested in the care of older adults to focus on the topic of cognitive health and aging. Summit participants specifically
examined questions of who should be screened for cognitive impairment and how they should be screened in medical settings. This is
important in the context of an acute illness given that the presence of cognitive impairment can have significant implications for care and
for the management of concomitant diseases as well as pose a major risk factor for dementia. Participants arrived at general principles to
guide future screening approaches in medical populations and identified knowledge gaps to direct future research. Key learning points of
the summit included:
• recognizing the importance of educating patients and healthcare providers about the value of assessing current and
baseline cognition;
• emphasizing that any screening tool must be appropriately normalized and validated in the population in which it is
used to obtain accurate information, including considerations of language, cultural factors, and education; and
• recognizing the great potential, with appropriate caveats, of electronic health records to augment cognitive screening
and tracking of changes in cognitive health over time.
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Introduction
The United States faces a dramatic demographic shift as its population ages, with important implications for health care
delivery and costs (Miquel et al., 2017). Age is a significant risk factor for many medical conditions, including cognitive
impairment and dementia, and as the number of people over age 65 increases, the number of people living with these condi-
tions will substantially increase (Prince, Comas-Herrera, Knapp, Guerchet, & Karagiannidou, 2016). Cognitive impairment is
of particular concern because it is a clinically dominant comorbidity influencing the presentation and management of concom-
itant conditions. Furthermore, people with cognitive impairment have been shown to use health care services in general and
specifically emergency department (ED) services more frequently and at higher cost than those without cognitive deficits
(LaMantia, Stump, Messina, Miller, & Callahan, 2016) and they utilize more outpatient visits compared to those without cog-
nitive impairment (Chung et al., 2014; St-Hilaire, Hudon, Preville, & Potvin, 2017). These individuals also experience com-
plications of co-existing medical conditions and have caregivers who experience substantial burden (Bradford, Kunik, Schulz,
Williams, & Singh, 2009). Cognitive impairment, which can be indicative of an acute condition, is often a precursor of
dementia, a longer term condition involving the development of impaired cognitive function in multiple domains which has
an impact on the individual’s daily life. Focusing on the broad condition of cognitive impairment as well as dementia and
Alzheimer’s disease is important given that many causes of cognitive impairment are reversible if identified early.
The expected increase in the number of people with sustained cognitive impairment and dementia portends a substantial
economic impact. Attempts to aggregate all associated elements of care to summarize the total costs of cognitive impairment
to individuals, families, and the nation as a whole is complicated due to diverse data sources and differing measurement meth-
odologies, among other factors. One of the most convincing estimates however can be generated for dementia care which re-
sults in the additional annual costs to the individual between $41,700 and $45,800 (adjusted for inflation in 2016 dollars) for
informal care and care purchased in the marketplace (Hurd, Martorell, Delavande, Mullen, & Langa, 2013). Of that amount,
the cost to individuals for their share of nursing home care totaled $15,300 and personal care in the home amounted to
$6,800. Moreover, at over $119.6 billion for a national total of dementia-related direct health expenditures, the costs of
dementia are similar to and in some cases exceed expenditures for heart disease and are substantially larger than the costs of
cancer (Hurd et al., 2013). This is a conservative estimate given that dementia is present in a more restricted population than
those people who experience significant cognitive deficits and come for treatment to the Emergency Department and Primary
Care office. Because of this substantial economic impact, detecting and acting on cognitive compromise early is an economic
imperative as well as a clinical necessity (Robinson, Tang, & Taylor, 2015) to improve the lives and care of people who live
with dementia and their care providers (Barnett, Lewis, Blackwell, & Taylor, 2014). Furthermore, the presence of cognitive
impairment has the potential to influence the effectiveness of doctor–patient communication, treatment adherence, the likeli-
hood of medical follow-up, selection of appropriate medications, and likely medication side effects, thereby impacting overall
health, which may add to caregiver burden and health costs.
Cognition should, therefore, be considered an important modifier of clinical outcomes and play an important role in clinical
assessment (Weintraub et al., 2014). Screening for cognitive impairment may uncover underlying remediable conditions, or
alert healthcare providers to increase surveillance for signs of progressive dementia. Identifying cognitive deficits and a de-
menting disease earlier allows for a more timely intervention, referrals to home and community-based services and social sup-
ports, and safeguarding health and financial management. The primary care setting is well positioned to provide early
recognition of cognitive impairment and dementia; however, early symptoms of dementia, such as memory impairment, are
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not always apparent during a routine office visit and may not be voiced by the patient as a complaint. As a result, cognitive
impairment and even frank dementia are often undiagnosed in primary care (Valcour, Masaki, Curb, & Blanchette, 2000;
Boustani et al., 2005; Borson, Scanlan, Watanabe, Tu, & Lessig, 2006; Bradford et al. 2009). For example, a 2011 survey
across 21 states found that 12.7% of adults over age 60 reported worsening memory problems in the prior 12 months, 35.2%
of whom acknowledged accompanying functional difficulties, but only 32.6% of these individuals had discussed their con-
cerns with a health care professional (CDC, 2013). Consequently, waiting for an expressed complaint may delay expeditious
investigation of underlying causes of impairment and addressing individual needs. Cognitive screening and diagnosis in the
ED and primary care settings could be beneficial to improve early detection and intervention and to initiate referrals to
community-based care and assistance with treatment planning. In addition, identifying the presence of underlying cognitive
impairment in older Emergency Department patients will have an impact on processes of care for them in the ED and impact
clinical outcomes since dementia is the main risk factor for delirium and other atypical presentations of acute disease.
Cognitive screening should not be limited to primary care and the ED as other specialty service clinics may also choose to
implement cognitive screening protocols. For example, it is noteworthy that the American Diabetes Association recently re-
commended screening for early detection of mild cognitive impairment or dementia for adults 65 years of age or older at the
initial clinic visit and annually as appropriate, recognizing the impact that cognitive impairment can have on diabetes manage-
ment, comorbidities, and activities of daily living (ADA, 2018)
Although it has been widely recognized that the use of cognitive assessment tools increases the detection of cognitive
impairment, which leads to early intervention, it is unclear how best to screen for cognitive impairment, including who should
be screened, what tools should be used, who would carry out screening, and what sequence of procedures would follow
screening (Cordell et al., 2013). Furthermore, it needs to be determined if a case-finding approach (i.e., using decision support
tools to detect “at-risk” individuals) should be employed versus a mass population screening approach to detect early cogni-
tive changes (Moyer & U.S. Preventive Services Task Force, 2014).
To examine how an interdisciplinary approach can best support the cognitive health of older Americans, the National
Academy of Neuropsychology sponsored a Geriatric Summit on Assessing Cognitive Disorders Among the Aging Population
on the 7th and 8th of December, 2017, in Denver, Colorado. The summit included an expert panel of speakers and partici-
pants representing the fields of neurology, neuropsychology, gerontology, geropsychiatry, primary care, emergency medicine,
psychology, collaborative care, social work, and nursing, disease advocacy and policy groups, governmental agencies and
providers, neuropsychological test publishers, and insurance providers. Participants came together to discuss the importance
of cognitive screening and how best to implement screening in the assessment of older adults coming to the primary care and
emergency room setting for medical care. This document summarizes the proceedings and content of the Summit and high-
lights the recommendations and key takeaways regarding unmet needs and future directions arrived at by the participants.
Demographics of the Aging Population of the United States
The population of the United States is aging. While 9% of the population was over 65 years of age in 1960, that proportion
is now 15% and will approach 25% by 2060 (Mather, Jacobson, & Pollard, 2015). The number of people over age 65 was
approximately 49 million in 2016 and is projected to be 98 million by 2060 (Mather et al., 2015). During that same period,
the number of people 85 years of age and older is expected to more than triple (Ortman, Velkoff, & Hogan, 2014; Mather
et al., 2015).
The older population is also becoming more diverse with respect to race and ethnicity (Ortman et al. 2014). Nationally, all
race and ethnic groups increased between 2015 and 2016 with the largest increase among the Asian and those self-identified
as multi-race groups (U.S. Census Bureau, 2017). In 2014, the great majority (more than 75%) of those over 65 years of age
were non-Hispanic white (Mather et al., 2015). The percent of people over age 65 who are Hispanic is expected to increase to
22% by 2060 (Mather et al., 2015). The increase in cultural, racial, and language diversity has important implications for the
delivery of care to older adults since care is improved when language concordance exists between individuals and their health-
care care providers (Fernandez et al., 2011; Tang, Lanza, Rodriguez, & Chang, 2011; Jih, Vittinghoff, & Fernandez, 2015;
Meuter, Gallois, Segalowitz, Ryder, & Hocking, 2015; Parker et al., 2017).
The regional and housing settings of older adults also have implications for health care delivery. The population over age
65 is not evenly distributed, tending to be located in certain parts of the country and to reach a higher proportion of the popu-
lation in rural counties (Mather et al., 2015). Only about 4% of this population live in institutional settings such as nursing
homes and a substantial proportion, as many as 56% of women and 30% of men over age 85, live alone in a personal home
(Mather et al., 2015) and 79.5% of householders age 65 and older owned their own homes as of 2016 (U.S. Cenus Bureau,
2018). For people living in rural areas, and as the number of older people living alone increases, there may be an associated
658 W. Perry et al. / Archives of Clinical Neuropsychology 33 (2018); 655–675
increase in the demand for services such as personal care and other home and community-based services (Mather et al., 2015)
and for technologies that allow people to receive some care remotely.
Importance of Cognition to Successful Aging
Maintaining cognitive health is important to successful aging. Age is the strongest risk factor for cognitive impairment
(Blazer, Yaffe, & Liverman, 2015; Moyer & Force, 2014). Cognition is multifactorial and encompasses memory, attention, lan-
guage, visuospatial skills, and executive functioning (Moyer & Force, 2014). Cross-sectional studies indicate that some aspects
of cognitive ability (specifically, measures of fluid ability and processing speed) appear to steadily decline with age across all in-
dividuals, starting at around 30 years of age (Miquel et al., 2017). Usually, this decline does not affect everyday function, per-
haps because people are able to maintain functional competence using cognitive abilities such as concrete knowledge that do not
decline or even improve with increasing age (Salthouse, 2012). There are, however, numerous “normal” age-related changes in
cognition that do affect the everyday function of older adults and place them at increased risk for functional and safety-related
difficulties. While there is vast heterogeneity in the cognitive abilities of older adults, significant cognitive decline can contribute
to errors in financial decision-making, impaired driving, and performance on technology-based tasks (Blazer et al. 2015).
Avoiding risk factors for cognitive impairment and dementing diseases should be prominent goals for healthcare.
The ability to recognize cognitive impairment is important for many reasons. Some underlying causes of cognitive
impairment, such as medication side effects or metabolic disorders, are potentially reversible. Early recognition of these con-
ditions can lead to effective treatment and improved quality of life for both the person and their family. Cognitive impairment
can affect adherence to treatment and lead to misuse of medications, which can lead to poor physical and emotional health
outcomes (Stilley, Bender, Dunbar-Jacob, Sereika, & Ryan, 2010). Consequently, detection of cognitive impairment would
allow healthcare professionals to modify their care pathways and provide education to improve treatment adherence (Arlt,
Lindner Rösler, & von Renteln-Kruse, 2008).
Additionally, specific recognition of mild cognitive impairment syndrome (MCI) is important because it is a risk factor for
progressive dementia, increasing its risk 10-fold (Belleville et al., 2017). Awareness of mild cognitive impairment can im-
prove surveillance for and detection of Alzheimer’s disease or other dementing diseases, and allow people access to clinical
trials and to better plan for the future, along with their families and caregivers (Sach-Ericsson & Blazer, 2015).
Sustained cognitive impairment and dementia are the main contributors to institutionalization in the older adult (Luppa
et al., 2008) and represent substantial health care costs (The Healthy Brain Initiative: The Public Health Road Map for State
and National Partnerships, 2013–2018, 2013). Given that healthcare resources are limited, informed decision making on
health care management and efficient allocation of resources are important to minimize loss of opportunities (Handels, Wolfs,
Aalten, Verhey, & Severens, 2013). For example, there is considerable research on redesigning systems of care intended to
promote more efficient, but equally effective, allocation of treatment resources (Callahan et al., 2014; French et al., 2014;
Long, Moriarty, Mittelman, & Foldes, 2014). These models commonly emphasize linkages with community resources and
multi-agency coordination including health care providers, dementia care managers, internet-based care management proto-
cols, and collaborative care planning with caregivers. Dementia is not the only area in which the force of economic reasoning
has been introduced. The cost of disease, benefits of testing and intervention, as well as cost-effectiveness and cost–benefit of
psychological assessment, were introduced and discussed at length by Yates and Taub (2003); Neumann (2004); Neumann
and Greenberg (2009); and Neumann and Weinstein (2010).
How to Detect Cognitive Impairment
The importance of identifying cognitive impairment is underscored by the inclusion, beginning in 2011, of assessment of
cognitive function as part of the Medicare Annual Wellness Visit (AWV) benefit, as authorized by the Patient Protection and
Affordable Care Act of 2010 (“Federal Register, Part II: Department of Health and Human Services, Center for Medicare &
Medicaid Services,” 2010). Medicare is statutorily prohibited from paying for routine physical checkups with certain excep-
tions, the “Welcome to Medicare” exam, and the “Annual Wellness Visit” (AWV), which became available in 2011. The
AWV includes and/or takes into account a health risk assessment and creates a personalized prevention plan that includes
establishment of, or update to, the individual’s medical and family history, a list of the individual’s current providers and sup-
pliers and medications prescribed; measurement of height, weight, body-mass index or waist circumference, and blood pres-
sure; detection of any cognitive impairment; establishment or update of an appropriate screening schedule for the next 5–10
years; establishment or update of a list of risk factors and conditions (including any mental health conditions) for which inter-
ventions are recommended or underway; and furnishing of personalized health advice and referral, as appropriate, to health
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education or preventive counseling services or programs. The regulation implementing AWV states that in order to detect in-
dividuals at risk for cognitive impairment, the health professional should use direct observation in combination with informa-
tion reported by the patient and/or concerns expressed by family and friends. In regard to cognitive screening, the U.S.
Preventive Services Task Force (USPSTF) has noted that evidence to date is not sufficient enough to support screening of
asymptomatic populations, nor is evidence sufficient to require the use of a specific tool. While no nationally recognized
screening tool for detection of cognitive impairments exists at the present time, continuing efforts to identify a standardized
screening methodology is needed. Still, relying simply on interview to detect cognitive impairment is insufficient given that
cognitive deficits may go undetected by health care professionals using interview alone (Chodosh et al., 2004).
In 2013, the Alzheimer’s Association published recommendations for implementing the detection of cognitive impairment
during the AWV through the use of objective cognitive measures rather than solely through voiced complaint or clinical
impression (Cordell et al., 2013). The recommendations include an algorithm that begins with assessing every patient for
signs or symptoms of cognitive impairment via medical records, observations, and concerns expressed by the patient or other
informant. Administration of a cognition assessment tool would follow unless both the patient and a knowledgeable informant
was present that affirmed cognition was normal (Cordell et al., 2013). If no knowledgeable informant is available at the visit,
a brief validated cognitive assessment tool should always be used. Several brief (<5 min) validated cognition assessment tools
are recommended as options since no single tool has been identified as best for this purpose (Cordell et al., 2013). If resulting
scores indicate concerns of cognitive impairment, the patient is referred for a full dementia evaluation (Cordell et al., 2013).
As mentioned above, in 2014, the USPSTF reviewed the evidence regarding screening the general population older than
65 years of age for cognitive impairment (Moyer & Force, 2014). The USPSTF arrived at an “I” rating (i.e., insufficient to
assess the balance of benefits and harms of the service) regarding screening, concluding that there was insufficient evidence
to weigh the benefits and harms of screening. Thus, routine screening of asymptomatic individuals may not be a common
practice at present. The Veterans Administration has released a fact sheet for clinicians recommending against general screen-
ing and recommended the use of “dementia warning signs” consistent with the recommendations of the National Institute on
Aging to identify patients who should be assessed for dementia (Clinician Fact Sheet: Detection of Dementia, 2011).
In 2015, The Gerontological Society of America (GSA) Workgroup on Cognitive Impairment Detection and Earlier
Diagnosis published a report and recommendations to improve the assessment of older adults for cognitive impairment during
visits with their primary care providers (The Gerontological Society of America Workgroup on Cognitive Impairment and
Earlier Diagnosis: Report and Recommendations, 2015). The purpose of the GSA report was to achieve earlier diagnosis of
Alzheimer’s disease and related dementias through increasing detection of cognitive impairment. The GSA recommendations
include a process for approaching the AWV, summarized as KAER: Kickstart the conversation, Assess for cognitive
impairment, Evaluate for dementia with full diagnostic workup if cognitive impairment is detected, and Refer to community
resources and clinical trials or other research, if appropriate. The GSA recommended the routine use of one of the structured
cognitive instruments recommended in the 2013 Alzheimer’s Association Report. Unlike the Alzheimer’s Association algo-
rithm, it recommended a structured cognitive instrument in all situations, even if a knowledgeable informant confirmed a
patient’s report that cognitive problems were not present.
The Summit: Summary of Issues Addressed
Seven presentations introduced important aspects of multidisciplinary topics including how and by whom cognition is as-
sessed, how assessment fits into current health care and reimbursement models, how electronic medical and health records
can facilitate assessment, and how assessment might differ depending on setting such as emergency versus primary care.
These presentations served as a basis for discussion after each talk and during the breakout groups that followed.
Opportunities for Improving Cognitive Assessment in Older Adults
A substantial amount of research has been devoted to the diagnosis of and screening for Alzheimer’s disease, a form of
progressive neurological disease causing dementia. In 1984, the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) Work Group pub-
lished criteria to refine the clinical diagnosis of Alzheimer’s disease, noting that improved diagnosis was required for thera-
peutic trials; at least 20% of people diagnosed with Alzheimer’s were found not to have the disease upon autopsy (McKhann
et al., 1984). The workgroup noted that no specific validated laboratory tests existed for Alzheimer’s disease. Over 30 years
later, this remains true today, though NIA-AA is moving towards a biological definition of Alzheimer’s disease (Jack,
Bennett, & Blennow, 2018) with the availability of CSF markers and pathologically validated brain imaging methods to detect
with a high degree of certainty the presence or absence of amyloid plaque pathology in the brain with using FDA-approved
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radiopharmaceuticals (Clark, Schneider, & Bedell, 2011; Jack, Albert, & Knopman, 2011; Jack et al., 2013; Varma et al.,
2018). Therefore, incorporating CSF and brain imaging biomarkers may be useful in the future.
Screening for cognitive impairment is quite different than screening for other medical conditions where a positive result
may be diagnostic of a true condition (e.g., a colonoscopy for colon cancer). In the case of cognitive screening the Summit
participants raised the concern that some may equate a positive screen with a diagnosis of dementia. Ashford and colleagues
(2006) explain that in regards to cognitive impairment “screening tests determine when diagnostic tests should be considered”
(p. 78). Detecting the presence of symptoms or signs of a disease does not require that formal diagnostic criteria be met.
Consequently a positive screen should “only lead [s] to a recommendation of a second step in assessment” (p. 78) which may
include imaging, neuropsychological testing, and activities of daily living assessments. Furthermore, there are many etiologies
of cognitive impairment and dementia and differential diagnosis may require different evaluation methods. The distinction
between tools for cognitive screening and diagnosis of dementia was a theme returned to frequently during the summit. Some
important differences between screening (e.g., brief assessment tools in the clinical setting) and diagnostic tools (e.g., neuro-
psychological testing, PET scan, etc.) for evaluating cognitive decline and dementia are summarized in Table 1.
Factors Influencing Diagnosis
It is well established that people with cognitive impairment and frank dementia often go undetected and are not properly
evaluated to arrive at a diagnosis. The substantial rate of under-diagnosis may be due in part to the attitudes of some primary
care physicians, who may be disinclined to diagnose something for which they feel there is a lack of useful interventions, as
well as to discomfort on the part of healthcare providers and patients around the idea of dementia (Ofri, 2014). Additionally,
most providers do not receive explicit training in how to identify cognitive impairment versus a diagnosis of dementia.
However there are training programs available to help health care professionals identify some of the clinical differences
between the major dementias (see: https://www.alz.org/health-care-professionals/dementia-diagnosis-diagnostic-tests.asp).
Still, both the steps necessary to arrive at a dementia diagnosis and the disclosure of this diagnosis to a patient and their fam-
ily can be time consuming and may require referrals for community resources. Patient and family/caregiver reluctance can
also contribute to under-diagnosis; many people who are referred for further diagnostic tests do not follow up and many peo-
ple would prefer not to know about a diagnosis for a condition with no available clinical treatment (Beck, 2012). Some feel
an early diagnosis is “cruel” because, without a more effective treatment, the benefits do not outweigh the harms (Beck, 2012;
Maguire et al., 1996), with potential harms to include a fear of loss of independence or of becoming a burden to family and
friends. However, it should be noted that other services and supports, including home and community-based services, are
available that may be beneficial to individuals with dementia and their caregivers.
In contrast, the World Alzheimer Report states that most people would wish to know about an Alzheimer’s diagnosis and
that earlier diagnosis can improve the care and support of patients with Alzheimer’s disease (Prince et al., 2016). A survey of
over 1,400 people found that most would take a test to predict a future disease, including Alzheimer’s disease, even if the test
were not perfect and even in the absence of more effective treatments (Neumann et al., 2012). Many people with Alzheimer’s
disease report they wish they had received an earlier diagnosis, before unrecognized dementia led to difficulties such as mis-
management of finances (Kolata, 2010).
Table 1. Differences between screening and diagnostic tools
Cognitive screening measures Diagnostic tests for dementia
Purpose of test Detect potential disease indicators Establish presence or absence of a specific
disease
Target
population
Large number of individuals selected on the basis of demographic or clinical characteristics
who are not previously diagnosed with the condition of interest
Symptomatic individuals, or those at high
risk
Test
characteristics
• Simple, acceptable to patients and staff
• Inexpensive; the benefit must justify the cost of screening large numbers of individuals
• May be invasive; precision of test
weighted more than its patient
acceptability
• May be expensive; cost is justified as
necessary to establish diagnosis
Positive result
threshold
Set to achieve high sensitivity (maximize potential positives) Set to achieve high specificity (minimize
false negatives)
Implication of
positive result
Suspicion of disease; in combination with other risk factors provides reason for additional
follow up
Provides definite diagnosis and thus
prognosis and identification of appropriate
management
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Early recognition of cognitive impairment may have benefits in addition to identification of people who are at higher risk and
should be monitored for Alzheimer’s disease. Cognitive impairment can increase the risk of cognitive side effects of medication
and as a predisposing factor increases the risk of a delirium with acute illness, medication side effects, or procedures. Some med-
ications may be contraindicated depending on the etiology of the dementia. In addition, cognitive impairment interferes with
treatment adherence and increases patient frustration. Awareness of the presence cognitive impairment allows healthcare provi-
ders to better watch for these effects and to change care plans accordingly. Appropriate management of chronic diseases that
require self-management, such as diabetes, also can be adversely affected if cognitive impairment is unrecognized or unad-
dressed (Sinclair, Girling, & Bayer, 2000). Modification of treatment and engaging family members and caregivers to assist in
supervising medications and care can be critical to reducing medication errors and preventable hospitalizations.
Who Should be Screened for Cognitive Impairment?
Although cognitive assessment is a benefit of the Medicare Annual Wellness Visit (AWV), the question of who should be
screened outside of that forum and how they should be screened remains controversial. As stated earlier, the USPSTF re-
viewed the available science and concluded there was insufficient information to enable them to assess the relative benefits
and harms of screening the general population of persons over 65 years of age for cognitive impairment (Moyer & Force,
2014). Therefore, the USPSTF made no recommendation regarding screening and noted that potential benefits of detection
and early intervention have small effects or a lack of published evidence. Some potential adverse side effects associated with
screening and current treatments were also noted (Moyer & Force, 2014). The Alzheimer’s Association has published recom-
mendations for implementing the cognitive assessment benefit of the AWV, including the recommendation that standardized
tools be used to make assessments because relying on clinical judgment is insufficient (Cordell et al., 2013). To help identify
who should be screened during an AWV when there is no patient complaint and a knowledgeable informant is not present, a
Dementia Screening Algorithm tool based upon dementia risk has been developed as an alternative to the Alzheimer’s
Association recommended algorithm (Barnes et al., 2014), although this algorithm has not been prospectively evaluated.
The USPSTF report stated that, because evidence for the long-term benefits of available treatments on cognitive outcomes
is not available, research into the effects of screening and early detection of mild to moderate dementia on decision making
and planning could provide support for general population screening of individuals over age 65 (Moyer & Force, 2014). A
single-blinded, randomized, controlled trial has been initiated to fill this knowledge gap identified by the USPSTF (Fowler
et al., 2014). This trial randomly assigned individuals to be screened for cognitive impairment as compared to usual care,
with those who screen positive referred for follow-up. Fowler and colleagues (2015) reported on an initial study of physician
behaviors when physician groups were randomized to receive information about a patient’s cognitive function based on re-
sults of neuropsychological testing compared to physician groups with treatment as usual. Although the response was modest,
physicians that received information about cognitive functioning were more likely to order blood tests to rule out reversible
cognitive impairment and to document discussions about cognition with their patients. Patients from this group were also
more likely to be on a cognitive-enhancing medication at follow-up. Rates of progression to dementia and cognitive outcomes
were not different across groups; however, authors note that longer term benefits of this nature may not be identifiable with
the relatively short study follow-up of 2 years compared with the long prodromal phase of Alzheimer’s disease. Results of
this initial study can be extrapolated to show potential benefits of cognitive screening in a primary care setting.
The American Academy of Neurology has recognized the important role of the Medicare Annual Wellness Visit in detect-
ing mild cognitive impairment. In its 2018 practice guideline “Update: Mild Cognitive Impairment” it recommends that when
performing a Medicare Annual Wellness Visit, clinicians should not rely on historical report of subjective memory concerns
alone when assessing for cognitive impairment and a brief, validated cognitive assessment instrument should be used (no spe-
cific instruments were recommended). The guidelines further recommend a formal clinical assessment and medical evaluation
to identify and treat MCI risk factors that are potentially modifiable (Petersen, Lopez, & Armstrong, 2018).
Improvements in assessment technology could also assist in collecting the needed information. For example, researchers at
Washington University in St. Louis, in collaboration with the Dominantly Inherited Alzheimer Network-Trials Unit, have created an
Ambulatory Research in Cognition (ARC) smartphone app to increase precision and reliability of cognitive assessment to help in clin-
ical trials. The app tests multiple aspects of cognition in short bursts multiple times per day; averaging the test results over time can
avoid placing too much weight on a single assessment that may be influenced by variables such as time of day. The test was designed
to minimize cultural and linguistic bias. Initial results indicate the app is feasible, reliable, and well tolerated (Hassenstab et al., 2017).
However, this was in a younger population, so it remains to be seen how feasible this will be for older adults.
Summit participants discussed the importance of combating some physicians’ feelings of helplessness about assessing cog-
nitive impairment and dementia and the need to provide information about benefits of early detection as well as solutions for
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patients who screen positive and their families and caregivers, as appropriate. They noted that the calculus of screening risks
and benefits changes entirely if effective interventions for dementia are identified. Given the lack of solutions however, they
emphasized the important need for the clinician to initiate conversations about brain health with the patient and their care-
givers, and to provide referrals for additional education and supportive community services.
Participants also noted the importance of broadening the discussion to include all cognitive impairment rather than strictly
focusing on Alzheimer’s disease. Though there may not be effective interventions for Alzheimer’s disease, many causes of
cognitive impairment are reversible and patients can see substantial benefit if the source of cognitive impairment is identified
early. An important aspect of early recognition of cognitive impairment is using tools validated with respect to language and
cultural factors.
Opportunities and Challenges of Assessing Cognition amidst Evolving Systems
The Centers for Medicare & Medicaid Services (CMS) is the largest purchaser of healthcare in the world, covering one-
third of Americans through Medicare, Medicaid, and the Children’s Health Insurance Program. Like the private sector, health
care service payments through CMS is moving from a fee-for-service model towards models that pay based on value rather
than volume. These new models are person-centered and outcomes-based, with incentives for improved outcomes (such as
reduced rates of hospital readmission) rather than volume and aim to support coordinated rather than fragmented care. In these
new models, a single payment may be based on an episode of care rather than multiple payments being made for every visit
and test that comprise an episode. Accountable Care Organizations (ACOs) and other integrated care models provide well-
coordinated health care services with payment that is adjusted up or down based on domains including quality performance
and reductions in the cost of care for the beneficiaries for whom ACO clinicians are accountable.
A goal of CMS is to empower patients and providers to make healthcare decisions. For coverage purposes, a diagnostic test
is coverable if there is sufficient evidence that the results from that test is useful in medical decision-making, and that the man-
agement ideally leads to clinically meaningful, improved outcomes. Although no one test is universally accepted as the best test
to detect cognitive impairment, several tests have been identified by the Gerontological Society of America (GSA) as satisfying
criteria including being relatively fast to administer and having been recently validated in the United States (The Gerontological
Society of America Workgroup on Cognitive Impairment and Earlier Diagnosis: Report and Recommendations, 2015). As
described earlier, the GSA provides a toolkit with information, instruments, and materials including videos to support PCPs in
implementing the KAER (Kickstart, Access, Evaluate and Refer) model. An important aspect of the KAER model is information
to support communication about cognitive impairment and dementia, including the fact that conditions such as depression that
often accompany dementia can be managed.
There are several payment vehicles for the assessment of cognitive impairment within the 2017 physician fee schedule.
New codes describe integrated behavioral health models including the psychiatric collaborative care model that involves coor-
dination between the PCP and a psychiatric consultant, behavioral health specialist, or behavioral health care manager. A new
code, G0505, was introduced in 2017 specifically to pay for the assessment of patients with cognitive impairment, including
dementia, and the creation of a care plan. Beginning in 2018 the G0505 code has been superseded with CPT code 99483
“Cognitive Assessment and Care Plan Services”. A requirement of this code is functional assessment and use of standardized
instruments for staging of dementia that incorporates most of the appropriate features of a cognitive evaluation to arrive at a
specific diagnosis. Importantly, this also sets the expectation that the caregiver is assessed for burden. Within the CMS
Quality Payment Program (https://qpp.cms.gov), clinicians can be rewarded either through a merit-based incentive system,
that includes quality measures specific to dementia care, or through participation in an advanced alternative payment model.
These alternative payment models may serve beneficiaries with dementia and caregivers well over time.
In October 2017, the US Department of Health and Human Services sponsored a Research Summit on Dementia Care in
which care models for people with a diagnosis of or at risk for dementia were presented. Common elements of many care
models included enhanced care coordination, enhanced access to care, referrals and access to home- and community-based
services, and caregiver services and support. A key takeaway is that a cognitive impairment care episode does not end with
screening, but must include all follow-up services, and define next steps and who is involved in those steps.
The Improving Medicare Post-Acute Care Transformation (IMPACT) Act standardizes data across post-acute care settings
such as long-term care hospitals and skilled nursing facilities to facilitate coordinated care and improve outcomes. The data
that should be collected to best manage cognitive impairment have yet to be determined.
Summit participants discussed challenges associated with current means of compensation and payment codes. One issue
that presents significant limitations is that Psychologists (including neuropsychologists, geropsychologists, rehabilitation psy-
chologists, etc.) are not included in the definition of care providers for this service and so are unable to bill using the G0505/
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99483 code for assessment services on which they are the experts. Within the new outcomes-based billing models such as
bundled services, such professionals may not be able to bill within a health system or practice group; thus, their expertise in
assessing for cognitive impairment may be excluded due to lack of reimbursement mechanisms. Psychologists, particularly
specialists within the psychology discipline, have critical skills and scientific knowledge that improve the cognitive screening
procedure. They can have a key role in advising healthcare facilities about which screening measures are appropriate, how
and where to set cutoff scores, teaching standardized administration of screening measures, and creating follow up trajectories
for individual healthcare systems including EDs and primary care facilities. The proportion of alternative models employing
team members who cannot bill Medicare directly is not known. In addition, it is not clear how to compensate for the increased
cost associated with linguistic complexity when assessing and caring for a beneficiary with limited English proficiency.
Predicting the Future with Clinical and Financial Data: Lessons Learned
Dr. Nirav Vakharia presented data from the Cleveland Clinic using an innovative approach to improve primary care, which
may be relevant to screening for cognitive impairment. The Cleveland Clinic defines the population for whose care it is
responsible to include the entire community, both those who seek medical care and those who do not. As an ACO, the
Cleveland Clinic has been successful at reducing hospital readmissions and reducing costs through coordinating care for high-
risk patients, including the use of intensive home care.
To find high-risk patients, Cleveland Clinic has focused on identifying and targeting conditions that lead to high,
unplanned utilization (as opposed to conditions which are known to be associated with high utilization such as cancer).
Clinical judgment was found to be inferior to a holistic model that included behavioral, functional, and social factors in addi-
tion to medical data. In this model, cognitive impairment, a behavioral factor, was the number one predictor of network leak-
age. Delirium was identified as a major factor that will likely predict risk of 30-day hospital readmission. In conclusion,
financial, social, behavioral, and functional data can be integrated with clinical data to create risk models to identify patients
who require increased coordination of care.
Summit participants discussed lessons that can be learned from the Cleveland Clinic experience regarding encouraging
Primary Care Physicians and health systems to conduct a cognitive assessment even if it takes time from a limited appoint-
ment. To support this effort the Summit participants discussed the importance of demonstrating the benefit of screening by
widely publicizing the data and its relevance; a strategy that has proven successful in the campaign to assess depression.
Another consideration that was widely discussed is making screening easier or more efficient by allowing for medical assis-
tants to conduct the screen and integrating the results directly into the electronic medical record. For example, in the
Cleveland Clinic system, if a delirium screen is positive, the medical record will prompt the clinician to consider adding delir-
ium to the problem list.
Assessing Cognitive Impairment in the Emergency Department
The Geriatric ED Collaborative (Funded by the John A. Hartford Foundation and the West Health Foundation) is an inter-
disciplinary group including clinicians, social workers, and nurses whose goal is to implement guidelines for the care of older
patients in emergency departments across the United States. In 2013, geriatric emergency department guidelines were
approved and published by the American College of Emergency Physicians, the American Geriatrics Society (AGS), the
Emergency Nurses Association, and the Society for Academic Emergency Medicine (Geriatric emergency department
guidelines, 2014). These guidelines recommend routine cognitive screening of older ED patients for both chronic and acute
cognitive impairment, (i.e. dementia and delirium) in those specialized emergency departments that have additional resources
and established systems of referral.
Screening the ED population is quite different from screening the general population. In the general population, screening
identifies mostly asymptomatic individuals who are at risk of a condition, while in the ED, the screening may more accurately
be called case-finding with the purpose of identifying a condition among a pre-selected population of patients. Also, the time
available for screening in the ED by a physician or other member of the interdisciplinary team is limited. Screening tools
must be of the type that can be administered by other trained healthcare staff and must address the practical limitations of the
environment such as assessing a patient who is lying on a gurney, is unable to sit up, unable to write, or even unable to
vocally respond (Schnitker et al., 2015).
Implementation of cognitive screening in the ED faces many barriers. Routine universal cognition screening, in the ED
may be challenging, even in individuals over the age of 65, due to environmental distractions, time and space constraints inad-
equate awareness and training of clinicians in recognizing cognitive impairment. Consequently, under ideal circumstances,
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routine cognition screening should be performed in a primary care or other professional outpatient setting. The suspicion of
cognitive impairment or dementia should however be included in the patient’s medical record, so subsequent providers may
be aware of the concerns of cognitive impairment and include that in their treatment planning. Identification of the patient’s
primary physician, and effective communication between clinicians in the off-hours can, at times, be difficult. However, iden-
tification of cognitive impairment in the ED may improve subsequent care by improving patient adherence and follow-up
thereby reducing reoccurring ED visits.
Finally, in the ED delirium must be assessed, as it represents a medical emergency. Similar to cognitive impairment in the
primary care setting, delirium is common in the ED and yet may not be the focus of the emergency physician’s primary rea-
son for attending to the patient and therefore not directly addressed (Elie et al., 2000; Hustey & Meldon, 2002; Lewis, Miller,
Morley, Nork, & Lasater, 1995). This is further complicated by the inability of ED physicians to admit a patient with the diag-
nosis of delirium or “altered mental status” as these conditions are caused by other underlying medical emergencies. The rec-
ognition of delirium specifically and cognitive impairment in general in older ED patients is important given its prevalence
(Hustey & Meldon, 2002; Wilber, 2006) and because it may be the principal symptom of a serious acute medical condition,
impacting the clinical evaluation, patients’ understanding of medical information, and compliance with discharge instructions
(Gerson, Counsell, Fontanarosa, & Smucker, 1994). Guidelines to implement geriatric-friendly processes of care in EDs rec-
ommend a two-step process for identifying delirium – a highly sensitive initial Delirium Triage Screen (DTS) followed by the
use of a highly specific Brief Confusion Assessment (b-CAM) tool, conducted by a member of the medical team (e.g., nurse).
A more in depth confirmatory assessment of potential delirium is then completed by another clinician (e.g, emergency physi-
cian, neurologist, neuropsychologist) for those screened positive at triage screen. However it is realized that not all EDs have
the additional resources to support this level of assessment of the older patient (Geriatric emergency department guidelines,
2014; Han et al., 2013). Summit participants fully supported the need to recognize delirium as well as cognitive impairment
and discussed the benefits of having an interdisciplinary team focused on geriatric care available. For example, systematic re-
views indicate that adding a nurse practitioner specialist improves care (Ament et al., 2015; Burl, Bonner, Rao, & Khan,
1998) as well as a care manager who can convey critical information to the next provider and access a referral network of ser-
vices if indicated. It was also acknowledged however, that consideration should be taken with the implications of ED clini-
cians introducing the diagnosing of dementia (chronic cognitive impairment) in older patients for whom they do not have an
established doctor–patient relationship. Delivery of such diagnoses to patients and their caregivers, in a setting where the
opportunity for interactive communication is often limited and would not allow for time to discuss the condition and its long-
term management.
Consistent with recommendation above, the American Academy of Neurology has recommended that neurology be con-
sulted in the ED and hospital for “high risk” cases in order to assess cognitive impairment using a delirium risk factor screen-
ing and preventive protocol (Josephson et al., 2017). The definition of “high risk” individuals for that measure includes both
predisposing and precipitating factors defined as one or more of the following: age 65 years or older, known major/mild neu-
rocognitive impairment, current hip fracture, severe illness (a clinical condition that is deteriorating or is at risk of deteriora-
tion), history of hypertension and/or alcoholism.
Current Trends: A Managed Care Perspective
In the changing landscape of medical care reimbursement, there are several trends relevant to understanding how cognitive
impairment assessment might be integrated in a managed care setting.
Many trends in managed care could be adapted to the care of cognitive impairment. Managed care is moving away from
pay for volume to pay for value, and is evaluating providers and making these data available to providers and patients.
Consequently, use of a cognitive screen to identify “at risk” individuals can be monitored and reported out as a component of
a necessary health report.
Furthermore, much can be learned by viewing collaborative care service models, such as the CMS Psychiatric
Collaborative Care Services Model (COCM https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-
MLN/MLNProducts/Downloads/BehavioralHealthIntegration.pdf). In this model, an enhanced rate is billed on a CPT code
and the billing practitioner shares the fee with the rest of the team, which can include a behavioral health care manager, psy-
chologist, or psychiatric consultant. Incorporating a multi-stage model in which positive results from either a performance
screen or an informant-based assessment is followed up by specialists (e.g., neurologist or neuropsychologist) can be of great
value (Galvin, 2018; Rosenbloom et al. 2016). In a recent study by Grober and colleagues (2016) a two-step cognitive screen-
ing approach using a brief battery of neuropsychological tests followed by a more extensive battery of neuropsychological
tests when the initial battery indicated impairment was highly beneficial in identifying primary care patients with early
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dementia. Using a two-step approach coupled with a care manager in the clinical setting could potentially lead to even greater
incremental cost-effectiveness.
Also in the pay-for-value models, providers may earn increased reimbursement or other benefits such as marketing support
through improved clinician metrics (such as improved quality measured through wellness assessments, or reduced average
cost per episode) or facility metrics (such as reduced readmission rate, or reduced average length of stay). Performance mea-
sures generally focus on three aims: improving health quality outcomes, improving overall population health, and reducing
healthcare costs (Berwick, Nolan, & Whittington, 2008). A fourth aim, improving patient satisfaction, is highlighted in the
Affordable Care Act, is sometimes included but is not always appropriate (Patient Protection and Affordable Care Act, 42
USC sec 1395ww 2015). For example, patient satisfaction may be difficult to measure for a provider whose work frequently
involves communicating diagnoses with poor prognosis.
To assist providers, Optum Health developed an online tool (ALERT) to provide real-time feedback regarding clinical and
claims data to identify outlier cases that may require increased interventions in order to avoid unnecessary medical interven-
tions. The Summit participants promoted the notion that use of a standardized neuropsychological assessment instrument as
part of a wellness assessment could potentially be adapted to assessment of cognition. To effectively use a tool such as
ALERT for cognitive impairment, an appropriate metric will need to be identified, which can then be leveraged to demon-
strate the utility of cognition assessment within the triple aim of improving population health, increasing patient satisfaction,
and reducing per-capita health care spending.
Additionally, the Summit participants recognized that while it is important for health care systems to assess cognition in
order to improve quality care and reduce expenses, it is also important to encourage patient and caregivers of the need for
assessment through education. Consequently for cognitive impairment, this may include educating patients and caregivers
about the benefit of early detection to avoid use of inappropriate medications and improve care of medical conditions and
early diagnosis of the cause of cognitive impairment so a care plan can be established. Summit participants also discussed cre-
ative approaches to encourage people to seek screening, such as cognitive impairment literature that could be sent to consu-
mers explaining the process and benefits of being screened. Primary care providers will also need to be educated regarding
the value of assessment. In the experience of Optum Health, adding even a 30-second application to every PCP visit elicited
pushback; thus, including screening for cognitive impairment would require education and payment incentives to encourage
clinicians and medical systems to provide cognitive assessment.
Using the Electronic Health Record in Assessment of Geriatric Patient Populations
The electronic health record (EHR) in general (also referred to as the CHR or Comprehensive Health Record) presents sev-
eral potential roles in population health approaches, such as screening for cognitive impairment. Currently, the federal govern-
ment requires that a minimum of 56 categories of data are shared between EHR platforms. This allows records to travel with
the patient, improving the capacity to track changes in health parameters such as cognitive impairment over time. The EHR
also allows the patient and all the clinicians involved in a patient’s care to access medical information in one place, increasing
the opportunities for coordination of interdisciplinary care.
The EHR can empower patients to see their test results, find discharge and follow-up instructions, post questions to their
care providers, and schedule reminders for medication. Dr. Alban from Epic indicated that patients access their EHR seven
times more frequently than care providers, and that the largest group accessing EHRs are 50- to 60-year-olds.
The EHR can incorporate hundreds of variables, collecting social or other information in addition to medical information.
In addition, many tools can be built into the CHR that would be relevant to screening for cognitive impairment, such as the
ability to conduct remote video visits from within a linked application, or the addition of risk assessment tools that assess vari-
ables from the EHR and make recommendations about screening or further evaluation. Summit participants agreed that there
needs to be standardized assessment tools and treatment plans that can be used across patient groups built into the EHR that
allow for clear clinical pathways including when it is recommended to refer out to a cognitive specialist.
Psychometric Challenges Associated with Assessing Cognition in Older Adults
One size does not fit all with respect to tests and tools used to assess cognition. The “best” assessment method will depend
on what is being assessed and why, and any assessment method must be appropriately validated and results compared to an
appropriate normative standard for the population being assessed. Results can vary substantially among different groups de-
pending on age, education, intelligence, and social factors, making a single test with an absolute cutoff that could be applied
to the entire adult population a challenging proposition. Psychometric considerations for selecting an assessment method
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include test reliability and validity, identification of correct normative reference values, test accuracy, and method of test
delivery (such as computerized vs. face-to-face testing).
Assessing cognitive impairment on the surface may appear to be straightforward, but given that cognitive impairment
ranges from mild cognitive diminishment to profound cognitive impairment, detection can widely vary. The most subtle of
these conditions, MCI, may or may not be detected by others, particularly if the patient is exceptionally verbal. However,
MCI does have adverse effects on cognitive function and should be reliably detectable by neuropsychological tests. The
DSM-5 defines two types of impairment, mild neurocognitive disorder (which corresponds to MCI) and major neurocognitive
disorder (which corresponds to dementia). These are defined as measured impairment in at least one cognitive domain, with
performance in the 3rd–16th percentile placing a patient in the mild category and at or below the 3rd percentile in the major
category. A recent analysis found a high false-positive rate in assessing for MCI, with almost 50% of the adults studied meet-
ing criteria for mild neurocognitive disorder as defined in the DSM-5 (Holdnack et al., 2017). In another study, using the rig-
orous neuropsychological battery (NAB) assessment, over 1/3 of healthy adults would be classified as having mild
neurocognitive disorder (Binder, Iverson, & Brooks, 2009; Iverson et al., 2008). Another study found 28% of people over age
75 met the criteria for MCI using only neuropsychological criteria that included low performance in at least two of ten tests,
and in comparing two approaches to detect MCI, found discordant results in almost 37% of cases (Saxton et al., 2009). These
studies highlight the importance of choice of assessment method and of test interpretation. Interpretation algorithms should be
optimized to meet the objectives of the assessment, and may need to be adjusted based on whether the false-positive (a test
result that incorrectly indicates cognitive impairment) or false-negative (a test result that incorrectly indicates the absence of
cognitive impairment) rate should be minimized so that selection criteria serves as an improvement over subjective complaints
and clinical judgment (see Edmonds et al., 2014, 2015, 2016). It is important to keep in mind that identifying precise criteria
is difficult because the performance of healthy and clinical groups will overlap.
To obtain valid data, tests must be delivered in a person’s primary language, and must be normalized within a representa-
tive population and results compared to an appropriate baseline. The participants recognized the overlooked fact that accord-
ing to the Census Bureau from the 2013 American Community Survey (ACS), 61.8 million Americans do not speak English
at home (https://www.census.gov/acs/www/data/data-tables-and-tools/). Because cutoffs for identifying impaired performance
will be defined relative to normative reference values it is essential to have an accurate measure of the distribution for a given
population. Normative results can vary depending on reading ability, occupation, language and culture. Summit participants
also emphasized the fact that many additional factors affect the results of a cognitive assessment including pain, lack of sleep,
fatigue, stress, anxiety, and depression, all of which must be considered when interpreting results.
Another consideration that must be acknowledged is that not all cognitive impairment is permanent and impaired cognitive
performance frequently returns to normal over time (Brooks, Iverson, Holdnack, & Feldman, 2008). Thus, future algorithms
need to become more sophisticated and adjust criteria for impairment dependent upon specific patient characteristics (Brooks,
Iverson, Feldman, & Holdnack, 2009).
While the summit participants were fully supportive of the need for cognitive screening, the consensus was that a cognitive
screening program must consider time and cost, the training and expertise required of those administering the screening, the
sensitivity and specificity of the screening method, and how or whether to monitor change in cognition over time. The group
recognized the potential for computerized testing which presents several advantages such as ease of use, standardization, and
the potential for automated scoring and interpretation, though results can depend on computer literacy (Iverson, Brooks,
Ashton, Johnson, & Gualtieri, 2009). The group however also recognized the need to consider the assessment from the per-
spective of the patient who may be computer-adverse or find the hospital room ED setting too distracting. In those cases,
paper and pencil testing or at-home evaluations may be preferable.
Breakout Groups
Following the presentations and discussions, the summit attendees broke into four focused groups to discuss the following
topics:
• The implementation of screening protocols in primary care and emergency department settings
• Identification of “at risk” patients: the role of registries and what occurs when a person tests positive on a screen
• Compensation for services – moving from fee-for-service to full risk and value-based payment models
• Next steps: creating clinical pathways for persons identified as potentially having a cognitive disorder
Further key takeaways from each group are described below.
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The Implementation of Screening Protocols in Primary Care and Emergency Department Settings
The Summit group determined that an effective cognitive screening protocol will need to differ based on clinical setting.
The group acknowledged that cognitive impairment in the ED typically falls into two important and ED-specific categories:
chronic, i.e. a likely dementing disorder, which impacts the care that patient receives by influencing ability to gather an accu-
rate history and perform an informative physical exam and the person’s ability to understand and participate in processes of
care and discharge planning; and acute, i.e. delirium, which is an essential ED presentation since it usually represents a symp-
tom of an acute occasionally life-threatening medical condition. Strategies for identifying them are significantly different in
the ED, however use of an initial and quick screening measure (preferably completed within one minute) could include an ini-
tial triage determination followed by an alternative screen in cases where delirium is suspected. Stress, pain, and other factors
frequently present in ED patients and can affect performance on cognitive screens; thus, alternative factors must be considered
when assessing cognitive impairment in the ED. In the primary care setting, a test may be able to take as long as 5 min and
should be considered as part of the AWV or any visit when there is a suspicion of memory concern. In the primary care set-
ting, novel approaches such as treating cognitive screening as a laboratory test (performed outside of the PCP office) may
present an alternative to finding time to conduct screening during an office visit.
In both settings, screening may be made more efficient by incorporating information about demographic and medical risk
factors from the patient’s EHR. A two-tiered approach could be considered in which initial demographic and medical risk fac-
tors apparent in the EHR are factored in to the algorithm to identify those with at high risk for cognitive impairment (Walters
et al., 2016). Once high-risk candidates are identified, they can be referred to a cognitive specialist (neurologist geriatrician,
geriatric psychiatrist, or neuropsychologist). Collateral information from informants also should be considered when
available.
Risk factors that might identify high-risk patients to guide cognitive screening in the primary care and ED settings include
age, history of stroke, educational attainment less than 12 years, depressive symptoms, presence of diabetes mellitus, sub-
stance abuse, and caregiver assistance needed for finances and/or medication (The Gerontological Society of America
Workgroup on Cognitive Impairment and Earlier Diagnosis: Report and Recommendations, 2015). Other neurological dis-
eases, such as a history of traumatic brain injury, multiple sclerosis, epilepsy, and Parkinson’s disease are at high risk of cog-
nitive impairment and could be included. Additional less-obvious factors that were identified included medication non-
adherence, frequent calls to the PCP office, and after visit summary confusion. The summit participants also recommended
future research to identify the optimal risk factors that could identify high-risk individuals and can be obtained from data in
the EHR.
Also, in both the ED and primary care setting, a care pathway should be readily available that identifies clear next steps
after positive findings. It may be inappropriate to rely on a single positive cognitive screen for dementia especially if per-
formed in a less-than-ideal setting, the ED. A strategy similar to that followed for identifying hypertension might be followed.
A diagnosis of hypertension requires a high blood pressure reading on at least two visits. A separate visit to verify cognitive
impairment with either another test instrument (for example the more extensive 30-point, 10–15 min Montreal Cognitive
Assessment) or an alternative version of the same screening instrument would also allow a clinical discussion and interpreta-
tion before initiating a full cognitive evaluation. Summit participants recognized that to encourage screen usage it would be
helpful to have more evidence that screening improves patient outcomes (such as reducing return visits to the ED or improv-
ing treatment adherence and care follow-up). In both settings, the care team should understand the benefit behind why the
screen is being done.
In all cases, the patient should be screened in their preferred language. If this is not possible, a risk factor-based algorithm
may be preferred to administering a screening test without language concordance because language discordance will likely
lead to false positive results. Language concordance has been demonstrated to improve outcomes, decrease medical errors,
improve treatment compliance, and decrease costs (Fernandez et al., 2011; Jih et al., 2015; Meuter et al., 2015; National
Standards for Culturally and Linguistically Appropriate Services in Health Care, 2001; Parker et al., 2017; Tang et al.,
2011). The summit group recommended that hospital systems identify the top five languages used by their population and pre-
pare for screening within these languages. This will involve identifying linguistic assets and implementing appropriate staff-
ing, instrumentation, and care pathways.
Additionally, the group recommended that screening tests be shown to be reliable and validated in different target popula-
tions, considering cultural factors in addition to language factors (Ardila, 2005; De Jesus-Zayas, Buigas, & Denney, 2012;
Romero et al., 2009).
A screening test for cognitive impairment should be able to be administered by any trained member of healthcare team.
Some levels of screening, such as The Eight-Item Informant Interview to Differentiate Aging and Dementia (AD8 dementia
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screening interview), or collecting written information from the patient, could be performed by medical technicians and office
staff. With proper training, medical technicians could complete other screening assessments.
The group recommended that the screening be characterized as a measure of brain health since screening tests are not diag-
nostic. It was also emphasized that having a geriatric trained behavioral health worker, or case manager (or a repurposed
member of the existing team) to walk the patient through the screening and subsequent follow-up could reduce recidivism
and decrease utilization. This will be increasingly important as compensation moves to full risk reimbursement models.
Identifying an advanced, technologically effective but least-cost method of screening and follow-up should be a priority area
of behavioral workforce policy (Garety et al., 2018; Nemec & Chan, 2017; Raney, Bergman, Torous, & Hasselberg, 2017).
The group stressed that the results of cognitive screening results should always be integrated into the EHR in a manner
that allows data to be captured for quality metrics, population health management, syndrome surveillance, and research. The
EHR may also be capable of scoring screening tests and offering suggested interpretation, optimizing clinician time.
Screening result interpretation should be available to all of a patient’s providers because as a dominant comorbidity cognitive
impairment influences the management and choice of drug treatment for all other conditions. This can be accomplished by uti-
lizing EHR problem lists to identify cognitive impairment, health maintenance tools and alerts, and condition registries. The
group recommended that EHRs create modules that include confusion and cognitive impairment screens so that hospital sys-
tems do not have to individually create such tools.
Identification of “At Risk” Patients: The Role of Registries and What Occurs When a Person Tests Positive on a Screen
The objective of screening for cognitive impairment is to improve patient care and outcomes for people with cognitive dif-
ficulties. The group emphasized that screening is not diagnostic; it provides important information to the clinician to make
informed decisions and to consider next step pathways. Ultimately the goal of screening is to lead to improved patient care.
In turn, screening combined with additional sources of information can lead to identifying remediable causes of cognitive
impairment that can be medically addressed; transition planning that can better ensure patient safety and adherence to recom-
mended treatment or follow up care; reduction in hospital, PCP, and ED use; and finally provide education, planning, and
support to the patient and family/caregiver to improve quality of life.
Identifying “at risk” patients differs depending on the medical setting. In the ED the primary goal may be to identify risk
to prevent, recognize, and treat delirium. In this setting, the patient may be best assessed by a primary ED nurse and if delir-
ium is identified, a pathway including evaluating underlying causes and deploying a care plan can be pursued. If there is a his-
tory of cognitive impairment or cognitive complaints, a delirium prevention protocol can be implemented (Josephson et al.
2017; Marcantonio, 2017). In the primary care setting, the primary goal may be to optimize adherence to personalized care
plans. Assessment may occur during the AWV or next care visit based on risk factors or response to brief targeted questions.
Positive screening results would lead to a pathway involving further assessment and additional support. While some patients
may not want to be told that they require a workup for cognitive impairment and a referral to a cognitive specialist such as
neurologist, studies have shown that patients experiencing cognitive problems favor being told that they have a cognitive
impairment and the possible cause of their problems (Elson, 2006).
A knowledge gap identified by the Summit group is what information to leverage from the EHR/CHR to identify at risk
patients in the primary care and ED settings. Registries comprised of databases may be used to fill this gap. The group how-
ever provided some cautionary thoughts about this approach and the ethics of identifying and classifying patients as “at risk”
without their knowledge.
The group agreed that the benefits of data-driven algorithms to identify people at risk for cognitive impairment outweighed
the potential unintended consequences. The EHR can assist in this process by ensuring that all older adult patients, whether a
member of an ACO or not, are evaluated on an annual basis. The resulting cognitive screening data can then be added to other
medical and non-medical, non-cognitive information such as, the presence of diabetes, medications that impact cognition,
age, reason for visit, and the number of phone calls or messages to clinicians, as well as psychological, functional, and social
areas. Once collected the data can then be used to build an algorithm to stratify patients on the basis of risk for cognitive
decline. Additional patients would be screened based on complaint of a change in cognition reported by the patient or family
member. Use of the EHR in this fashion can also minimize the implicit bias that can be present in the primary care setting
which affects the rates at which different patients are referred to specialist for follow up.
The summit group agreed that once an algorithm is empirically determined it should be reexamined to ensure that it is pro-
viding a valid procedure at each location or whether geographic distinctions need to be accounted for. The group asserted that
ideally there needs to be a care pathway to direct follow up after screening, including clear guidelines on how often follow up
assessments need to be conducted based upon a screening result in combination with other factors. Furthermore, health sys-
tems should aspire to include some type of care team follow-up or contact via phone call.
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Compensation for Services – Moving from Fee-for-Service to Full Risk and Value Based Payment Models
This group emphasized that screening is different from assessment or diagnosis. Screening as part of a collaborative care
pathway fits well into multispecialty, longitudinal episodes of care models and bundled payment models. However, the care
team should include non-physician clinicians not eligible for Medicare reimbursement for this service (e.g., psychologists)
because they have expertise in cognitive assessments. These care and payment models that bundle services over longitudinal
episodes or that are delivered by a team of professionals may deliver improved health outcomes for dementia patients and
their caregivers, but require further study.
Presently insurance companies are contending with bottlenecks to care, as demand increases while simultaneously access
to care decreases. Incentives for the system to evaluate more patients could incorporate care pathways and opportunities for
physician “extenders” to provide care to reduce physician burden and facilitate care across settings. For cognitive screening,
this could involve offering higher reimbursement for initial evaluations for at-risk individuals, and additional payments for
practices furnishing higher levels of care. Telehealth services might also be leveraged to reduce caregiver burdens, especially
when delivering care to patients living in rural or isolated settings, or when language concordance is of issue. Early detection
or diagnosis has the potential for cost saving and redirection of resources to those with the most pressing health related pro-
blems. This possibility deserves further study. Alberdi, Aztiria, and Basarab (2016) have recently addressed this as a cost sav-
ing issue with respect to the early diagnosis of Alzheimer’s disease. As for dementia, in a letter to the editor discussing the
benefits of early diagnosis, the editor of the International Journal of Geriatric Psychiatry asserts that “…interventions can
take place to avoid crises” and “[the] economic benefit–avoiding unnecessary admissions and institutionalization–is well
known” (Burns, 2012, e3556). If “planning” has the positive attributes suggested for most future activities it would appear
that early detection of dementia would clearly help avoid excessive and unnecessary costs.
Next Steps: Creating Clinical Pathways for Persons Identified as Potentially Having a Cognitive Disorder
The final group noted that designing clinical pathways assumes the correct population was screened using a valid and accu-
rate test. As stated above, reasons for potential false positives should always be included in the interpretation of results and
considered before proceeding.
Immediate next steps will depend on the clinical setting and the severity of the screening result. In the ED, an established
clinical care pathway should be implemented for delirium prevention and delirium treatment that includes a strategy for asses-
sing potential causes as well as for the management of the condition. In this regard the pathway could include determining
acute care needs and the need for admission but also remind providers to establish surrogate decision makers, and to consult
with a cognitive specialist on the team. When a screen for cognitive impairment is positive but delirium is not present, the
care pathway would include obtaining information from available sources such as collateral informants. A care manager or
social worker might be activated to direct the patient to appropriate resources and help ensure compliance with follow-up
plans.
In the ED, positive screen results affect clinical decision making in the design or modification of care plans taking into
account the patient’s capacity for decision making or understanding, assessment of safety for discharge, identification of dis-
charge considerations such as who will be helping to care for a patient, providing written information to the patient and fam-
ily/caregiver and referrals to appropriate resources, and increasing follow up. A positive screen may also trigger assessment
by an interdisciplinary team, referral to follow-up for cognitive disorder or dementia, or referral to outpatient treatment if
behavioral issues are predominant. Assessment via an interdisciplinary team, including social work and clinical care man-
agers, may also generate referrals to home and community-based services and social supports.
In the primary care setting, a positive screening result would result in implantation of a care plan in line with existing
guidelines from sources such as the AGS and Alzheimer’s Association or specific to the healthcare system. The plan should
include confirming cognitive impairment on a second visit, identifying and treating remediable causes of cognitive
impairment, and determining a specific protocol for how cognition would continue to be monitored over time, and when a
referral to a specialist is indicated. Specialist referrals may be triggered by atypical presentations and behavioral dysregulation
and would rely on recommendations from existing guidelines. Specialist referrals also would be appropriate if performance
and interpretation of a cognitive evaluation to determine the cause of impairment is outside the provider’s scope of practice.
Specialists such as neurologists, geriatric psychiatrists, geriatricians, and neuropsychologists can be called on to clarify diag-
nosis, conduct further testing to inform treatment and track response to treatment, and to address emotional distress and envi-
ronmental adjustment, provide education, and caregiver support. Specialist availability will depend on available resources, so
any care plan must provide flexibility for settings with no access to certain specialists. This group emphasized the value for
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patients with cognitive impairment of care managers who can organize care, provide educational information and materials,
direct patients to community resources and other social supports, and address functional needs that can minimize risks of
decline.
Many types of educational materials can be provided to patients and their families and caregivers. The information should
be adapted as needed for patient and caregiver. Helpful materials may include:
• Condition-specific information (e.g., symptoms, expected progression, etc.)
• Caregiver resources and support (includes respite and social support)
• Community Resources (e.g., adult day health, community/senior centers, adaptive sports programs, paratransit ser-
vices, Neuro Recovery centers, etc.)
• How to manage functional limitations, supervision needs, and behavioral changes
• Safety Issues within home and community
• Advance Care Planning (e.g., POA, Living will, Guardianship)
• Referral to existing information sources (e.g., Alzheimer’s Assoc., Council on Aging, AARP, etc.)
• Empirically validated options to promote positive cognitive health (e.g., exercise, social and community involvement,
healthy diet, cognitively stimulating activities, etc.)
• Information about sleep – importance of healthy sleep patterns and risks for cognition related to disrupted sleep
Key Takeaways and Knowledge Gaps
In conclusion, the Summit attendees emphasized the power of an interdisciplinary approach to improve care and the signifi-
cant range of expertise available when professional organizations come together. To summarize, the key takeaway conclu-
sions are listed in Table 2.
Furthermore, the Summit participants identified knowledge gaps that exist which can be the basis for future collaborative
research endeavors (see Table 3).
For economists, an increase in the number of options or an expansion of the data set often provides a basis for a more effi-
cient and quite possibly a lower cost solution to accomplishing an objective. Even where a final resolve is not available, early
detection at least could improve the prospects for better quality of life associated with a cognitive impairment diagnosis. With
Table 2. Key takeaway conclusions
• There is a need to educate the public regarding the difference between screening, which identifies individuals at risk within an asymptomatic population,
and diagnosis of a specific condition such as delirium or a dementing disease.
• It is important to emphasize that cognitive impairment screening is a measure of brain health, which needs to be monitored regularly in at-risk individuals
to determine the fidelity of brain functioning.
• Cognitive impairment in older adults has multiple possible causes, including medical and psychiatric conditions, such as endocrine and metabolic
conditions, chronic pain, depression, sleep disturbance, medication side-effects, delirium, and brain diseases causing dementia, with Alzheimer’s disease
and MCI being the most common.
• Cognitive impairment is a clinically dominant comorbidity. Cognitive impairment is so serious that it overshadows the management of other health
problems. It influences the effectiveness of doctor–patient communication, treatment adherence, the likelihood of medical follow-up, the selection of
appropriate medications, and likely medication side effects.
• Cognitive evaluation to determine the causes and remediable factors contributing to impairment is necessary to guide appropriate choice of medications
and management.
• Collaborative care models that include the expertise of specialists in the area of cognitive assessment (i.e., neuropsychologists, neurologists and
geropsychiatrist) may be cost-effective and provide better quality care. In the emerging value over volume payment models, inclusion of cognitive
specialists fits well into new team-based payment models that emphasize overall wellness.
• The EHR presents a great deal of promise for risk stratification modeling and for monitoring changes in cognitive screen performance over time. EHR
automated tools for assessing and recording the results of individual’s cognition over time need to be developed.
• There is a need to increase awareness of identifying risk factors beyond medical data that include social, behavioral, and functional information.
• No one size fits all when assessing for cognitive impairment. It is important to recognize that the goals and means of cognitive assessment depend on the
clinical setting and differ between the ED and the primary care environment.
• There is an important role that care managers or coordinators play in ensuring that people stay on a care pathway, and may also increase patient and
caregiver satisfaction.
• There are deficiencies in health services in rural and economically disadvantaged America, resulting in a large gap in access to care and differences in
resources such as care coordinators and cognitive specialists.
• Assessment of cognition must be done in a linguistically and culturally appropriate way to obtain meaningful results.
• There is a great need to increase advocacy regarding Medicare coverage and payment for a range of services and supports for beneficiaries with cognitive
impairment (for example, including reimbursement for psychologists on interdisciplinary teams).
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respect to Alzheimer’s disease, Barnett and colleagues (2014) studied early identification of cognitive loss within a cost-
effectiveness context and found that net economic benefits were reduced by approximately 17% for every year of delayed
identification.
Finally, the Summit participants suggested follow up meetings to track success in the assessment of cognitive disorders
among the aging population. The participants expressed hope that the proceedings from this meeting will provide practitioners
and health systems with useful guidelines to consider when developing clinical practice pathways. Given the complexity of
clinical decision-making, diversity of services required, and the need for coordination of services for the person experiencing
cognitive impairment, implementation of a team-based, collaborative care approach may best serve to improve the identifica-
tion and care of people with cognitive disorders.
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